FDA pharmacologic class
Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme
5 medicines are in FDA's class of hydrolytic lysosomal glycosaminoglycan-specific enzymes: elosulfase alfa (Vimizim), galsulfase (Naglazyme), idursulfase (Elaprase), laronidase (Aldurazyme) and tividenofusp alfa (Avlayah). 0 of the 5 are listed from generic labelers (FDA NDC Directory, October 8, 2026).
Which medicines are hydrolytic lysosomal glycosaminoglycan-specific enzyme?
| Medicine | Brand names | Generic labelers (all forms) | Pharmacy cost | Boxed warning | Shortage | Recalls since 2012 |
|---|---|---|---|---|---|---|
| Elosulfase alfa | Vimizim | none listed | n/a | Yes | No current entry | 0 |
| Galsulfase | Naglazyme | none listed | n/a | Yes | No current entry | 0 |
| Idursulfase | Elaprase | none listed | n/a | Yes | No current entry | 0 |
| Laronidase | Aldurazyme | none listed | n/a | Yes | No current entry | 0 |
| Tividenofusp alfa | Avlayah | none listed | n/a | Yes | No current entry | 0 |
Source: FDA Established Pharmacologic Class (NDC Directory, openFDA); CMS NADAC of October 7, 2026; FDA shortages and recalls (FDA files October 8, 2026)